ReviewBreast cancer (Tokyo, Japan)2026

Next-generation endocrine therapy in HR+/HER2 - breast cancer: oral SERDs, ER-targeting innovations, and ctDNA-driven ESR1 mutation-guided switching.

Nan Yao et al.PubMed ↗Publisher ↗

No numbers read from the abstract.